Doxorubicin-induced cell cycle arrest and apoptosis in HL-60 leukemia cells – a narrative review
DOI:
https://doi.org/10.15584/ejcem.2025.4.30Abstract
Introduction and aim. Doxorubicin is an anthracycline widely used in cancer therapy. Although the complete mechanism of action of doxorubicin is not fully understood, it is known to effectively destroy cancer cells by intercalating into DNA. This article aims to evaluate the anticancer effect of doxorubicin with particular emphasis on HL-60 leukemia cells and cell cycle/apoptosis.
Material and methods. This narrative review contains a collection and evaluation of peer-reviewed publications on the anticancer properties and therapeutic applications of doxorubicin. It focuses on doxorubicin-induced cell cycle arrest and apoptosis in HL-60 leukemia cells, with particular emphasis on toxicity and resistance. A literature review was conducted using the following databases: PubMed and Google Scholar.
Analysis of the literature. Doxorubicin exhibits potent anticancer activity against many cancer types. Unfortunately, due to serious side effects, primarily related to the cardiotoxicity of the drug, its potential cannot be fully exploited.
Conclusion. In recent years, many approaches have been developed to circumvent the limitations of doxorubicin. Identifying all the pathways of doxorubicin action is important for planning combination therapy, mitigating side effects, and developing new drugs. However, further clinical studies are needed to determine their long-term safety and efficacy.
Downloads
References
Cieślik A. Epidemiology of leukaemias in Poland. Stud Med. 2011;21(1):53-60.
Wafa A, Moassass F, Liehr T, Al-Ablog A, Al-Achkar W. Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report. J Med Case Rep. 2016;10:203. doi:10.1186/s13256-016-0982-8.
Wang Z, Chen Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood. 2008;111(5):2505-2515. doi:10.1182/blood-2007-07-102798
Podhorecka M, Macheta A. Acute promyelocytic leukemia - modern approach to disease pathogenesis and differentiation treatment. Postepy Hig Med Dosw (online). 2013;67:1083-1089. doi:10.5604/17322693.1077467
Seferyńska I, Warzocha K. A registry report from the Institute of Hematology and Transfusion Medicine on adult morbidity for acute leukemias between 2004–2010 in Poland made on behalf of the Polish Adult Leukemia Group (PALG). Hematologia. 2014;5(2):162-172. doi: 10.5114/hcp.2014.44988
Sanz MA, Martín G, González M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-1243. doi:10.1182/blood-2003-07-2462
Saeed S, Logie C, Stunnenberg HG, Martens JH. Genome-wide functions of PML-RARα in acute promyelocytic leukaemia. Br J Cancer. 2011;104(4):554-8. doi: 10.1038/sj.bjc.6606095.
Wierzbowska A. Ostra białaczka szpikowa. Onkol Prakt Klin – Edukacja. 2020;6(A):119-144. doi:10.5603/owpk_edu.70553
Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther. 2014;10(4):853-858. doi:10.4103/0973-1482.139267
Johnson-Arbor K, Dubey R. Doxorubicin. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Denard B, Lee C, Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife. 2012;1:e00090. doi:10.7554/eLife.00090
Patel AG, Kaufmann SH. Cancer: How does doxorubicin work? eLife. 2012;1:e00387. doi:10.7554/eLife.00387
Hou W, Liu Y, Liang H, Wu S. Induction of differentiation of the acute myeloid leukemia cell line HL‑60 by SN3‑L6 and all‑trans retinoic acid. Cell Death Discov. 2020;6:84. doi:10.1038/s41420-020-00354-3
Basu J, Madhulika S, Murmu KC, Mohanty S, Samal P, Das A, Mahapatra S, Saha S, Sinha I, Prasad P. Molecular and epigenetic alterations in normal and malignant myelopoiesis in human leukemia 60 (HL60) promyelocytic cell line model. Front Cell Dev Biol. 2023;11:1060537. doi:10.3389/fcell.2023.1060537.
Sewastianik T, Prochorec-Sobieszek M, Juszczyński P. Deregulation of MYC transcription factor in lymphoid tumors — molecular, pathogenetic, clinical and therapeutic implications. Hematologia. 2012;3(4):313-326.
Reece JB, Urry LA, Cain ML, et al. Campbell Biology. 10th ed. Poznań: Dom Wydawniczy REBIS; 2016:234-249.
Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double‑edged sword. J Exp Clin Cancer Res. 2016;35:153. doi:10.1186/s13046-016-0433-9
Israels ED, Israels LG. The cell cycle. Oncologist. 2000;5(6):510-513. doi:10.1634/theoncologist.5-6-510
Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2011;226(2):352-364. doi:10.1002/path.3022
Gąsior Ł, Daszkiewicz R, Michniak K. Role of gamma H2A.X in reproductive cells. Postepy Biol Komór Cell. 2016;43(1):53-72.
Gilewski TA, Dang C, Surbone A, et al. Cytokinetics. In: Bast RC Jr, Kufe DW, Pollock RE, et al., editors. Holland-Frei Cancer Medicine. 5th edition. Hamilton (ON): BC Decker; 2000. pp 511-538.
Gasińska A, Biesaga B. The two aspects of tumour hypoxia. Nowotwory J Oncol. 2010;60(4):332. doi:10.5603/njo.52151
Afford S, Randhawa S. Apoptosis. Mol Pathol. 2000;53(2):55-63. doi:10.1136/mp.53.2.55
Kopiński P, Chorostowska-Wynimko J, Dyczek A, Giżycka A. Apoptosis of alveolar lymphocytes. Part 1: pathways of lymphocyte apoptosis. Adv Respir Med. 2014;82(2):170-182. doi:10.5603/PiAP.2014.0023
Żuryń A, Grzanka A, Stępień A, Grzanka D, Dębski R, Smoliński D. Expression of cyclin A in human leukemia cell line HL-60 following treatment with doxorubicin and etoposide: the potential involvement of cyclin A in apoptosis. Oncol Rep. 2007;17:1013-1019. doi:10.3892/or.17.5.101
Stenzel A, Żuryń A, Grzanka AA, Grzanka A. Cyclins as a markers of cancer diseases. Nowotwory J Oncol. 2012;62(2):115-122. doi:10.5603/njo.19142.
Suzuki F, Hashimoto K, Kikuchi H, et al. Induction of tumor-specific cytotoxicity and apoptosis by doxorubicin. Anticancer Res. 2005;25:887-894.
Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155-162. doi:10.1159/000265166
Sheibani M, Azizi Y, Shayan M, et al. Doxorubicin-induced cardiotoxicity: An overview on pre-clinical therapeutic approaches. Cardiovasc Toxicol. 2022;22:292-310. doi:10.1007/s12012-022-09721-1
Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263-302. doi:10.2165/00002018-200022040-00002
Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12:339. doi:10.1038/s41419-021-03614-x
Kong CY, Guo Z, Song P, Zhang X, Yuan YP, Teng T, Yan L, Tang QZ. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int J Biol Sci. 2022;18(2):760-770. doi:10.7150/ijbs.65258
Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222-2229. doi:10.1002/cncr.23071
Ben-Aharon I, Bar-Joseph H, Tzarfaty G, et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol. 2010;8:20. doi:10.1186/1477-7827-8-20
Kostrzewa-Nowak, D., Paine, M., Wolf, C. et al.The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer, 2005;93:89-97.doi:10.1038/sj.bjc.6602639
Al-Abbasa NS, Shaer NA. Combination of coumarin and doxorubicin induces drug-resistant acute myeloid leukemia cell death. Heliyon. 2021;7:e06255. doi:10.1016/j.heliyon.2021.e06255
Chen J, Wei H, Cheng J, et al. Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells. Oncol Lett. 2018;15(2):1255-1262. doi:10.3892/ol.2017.7353
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
